Toll Free Helpline (India): 1800 1234 070
Rest of World: +91-9810852116
Free Publication Certificate
Submit Manuscript
Journal code(s)
- E-ISSN Number: 2277-7695
- P-ISSN Number: 2349-8242
- CODEN Code: PIHNBQ
- ZDB-Number: 2663038-2
- IC Journal ID: 7725
Main Menu
Special Issue
Copyright Form
Identifier
Vol. 12, Issue 5 (2023)
Albendazole encapsulation along with quercetin in chitosan-alginate microspheres enhances bioavailability and sustained release in broilers
Author(s):
Bhadraiah A, Dr. G Dilip Reddy, Dr. K Bharavi, Dr. V Rama Devi and Dr. P Ravi Kumar
Bhadraiah A, Dr. G Dilip Reddy, Dr. K Bharavi, Dr. V Rama Devi and Dr. P Ravi Kumar
Abstract:
The present study investigated the pharmacokinetics of Albendazole (ABZ) administered orally along with quercetin in chitosan-alginate encapsulated microspheres to broilers. Thirty two adult broilers were divided into four groups with eight birds in each group and treated with 10mg/kg b.wt pure albendazole orally to group I and intravenously to group II while groups III received chitosan alginate microspheres impregnated with albendazole (CS-ALG-ABZ) equivalent to deliver 10 mg/kg of ABZ and group IV received chitosan alginate microspheres impregnated with albendazole and quercetin (CS-ALG-ABZ-QUE) equivalent to deliver 10 mg/kg b.wt. of ABZ. Plasma separated from blood samples collected at various intervals for HPLC estimation of ABZ and albendazole sulphoxide (ABZ-SO) to carry out pharmacokinetic analysis by non-compartmental model.
The present study investigated the pharmacokinetics of Albendazole (ABZ) administered orally along with quercetin in chitosan-alginate encapsulated microspheres to broilers. Thirty two adult broilers were divided into four groups with eight birds in each group and treated with 10mg/kg b.wt pure albendazole orally to group I and intravenously to group II while groups III received chitosan alginate microspheres impregnated with albendazole (CS-ALG-ABZ) equivalent to deliver 10 mg/kg of ABZ and group IV received chitosan alginate microspheres impregnated with albendazole and quercetin (CS-ALG-ABZ-QUE) equivalent to deliver 10 mg/kg b.wt. of ABZ. Plasma separated from blood samples collected at various intervals for HPLC estimation of ABZ and albendazole sulphoxide (ABZ-SO) to carry out pharmacokinetic analysis by non-compartmental model.
ABZ could not be detected in Group-I at any point of time, while in other three groups ABZ was detectable up to 9-12h after administration. The Cmax of ABZ in groups II and IV was significantly higher when compared to group III, while tmax was significantly higher in group IV when compared to groups II and III. The AUC observed in group IV was significantly (~2.5 fold) higher compared to groups II and III. The volume of distribution and clearance of ABZ in group IV was significantly lower when compared to groups II and III.
Albendazole sulphoxide, the active metabolite of albendazole, could be detected from one hour to 48 h in group IV compared to 0.5 to 36 h in group I, 0.083 to 36 h in group II and 0.5 to 48 h in group III. The pharmacokinetics of ABZ-SO revealed a significantly higher t½ and Cmax in groups III and IV when compared to group I.
The AUC observed in group II, III and IV was significantly higher compared to group I though the AUC observed in group IV was non-significantly lower than that of group III. The MRT observed in group IV was longer than that observed in groups I and II. Similar to its parent compound ABZ-SO also showed similar trend with respect to Vd and clearance.
The results in present study indicate that the quercetin increased the absorption of ABZ and decreased its metabolite formation probably by inhibiting intestinal/hepatic CYPs. The formulation containing quercetin prolonged the absorption and elimination of the active metabolite of ABZ-SO as evidenced by increased Cmax, AUC, and MRT observed in groups III and IV.
In conclusion ABZ absorption enhanced with relative improvement in bioavailability of its active metabolite albendazole sulphoxide by administering chitosan alginate microspheres impregnated with albendazole along with quercetin.
Pages: 3717-3723 | 292 Views 135 Downloads
How to cite this article:
Bhadraiah A, Dr. G Dilip Reddy, Dr. K Bharavi, Dr. V Rama Devi, Dr. P Ravi Kumar. Albendazole encapsulation along with quercetin in chitosan-alginate microspheres enhances bioavailability and sustained release in broilers. Pharma Innovation 2023;12(5):3717-3723.
Journal code(s)
- E-ISSN Number: 2277-7695
- P-ISSN Number: 2349-8242
- CODEN Code: PIHNBQ
- ZDB-Number: 2663038-2
- IC Journal ID: 7725
Main Menu
Special Issue
Copyright Form
Identifier
The Pharma Innovation Journal
